# Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis

> **NCT04261023** · PHASE2 · TERMINATED · sponsor: **University of Leeds** · enrollment: 6 (actual)

## Conditions studied

- Inflammatory Arthritis

## Interventions

- **DRUG:** Orencia 125 MG Per 1 ML Prefilled Syringe

## Key facts

- **NCT ID:** NCT04261023
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-24
- **Primary completion:** 2021-03-15
- **Final completion:** 2021-03-15
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The CI terminated ARCADIA early due to a number of reasons. These include the difficulty in recruiting and being placed on pause during the COVID pandemic, plus limited staffing at that time \& the need to considerably amend the eCRF MACRO system
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04261023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04261023, "Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04261023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*